BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Won JK, Keam B, Koh J, Cho HJ, Jeon YK, Kim TM, Lee SH, Lee DS, Kim DW, Chung DH. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol 2015;26:348-54. [PMID: 25403583 DOI: 10.1093/annonc/mdu530] [Cited by in Crossref: 99] [Cited by in F6Publishing: 113] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
2 Wang T, Wei L, Lu Q, Shao Y, You S, Yin JC, Wang S, Shao Y, Chen Z, Wang Z. Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling. npj Precis Onc 2022;6:84. [DOI: 10.1038/s41698-022-00325-0] [Reference Citation Analysis]
3 Wang H, Zhu S, Li Z, Qi X, Zhang L, Ke L, Lin Y. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report. Medicine 2022;101:e30316. [DOI: 10.1097/md.0000000000030316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. Ann Oncol 2022:S0923-7534(22)00112-0. [PMID: 35176458 DOI: 10.1016/j.annonc.2022.02.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
5 Behel V, Noronha V, Patil V, Menon N, Chandrani P, Kumar R, Rastogi S, Mahajan A, Chougule A, Dutt A, Prabhash K. Molecular tumor board–guided treatment of non-small-cell lung cancer with dual driver (ALK and EGFR) alterations. Cancer Res Stat Treat 2022;5:312. [DOI: 10.4103/crst.crst_114_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Guaitoli G, Bertolini F, Bettelli S, Manfredini S, Maur M, Trudu L, Aramini B, Masciale V, Grisendi G, Dominici M, Barbieri F. Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations. Int J Mol Sci 2021;22:12867. [PMID: 34884672 DOI: 10.3390/ijms222312867] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Selvarajan G, Jayachandran PK. Dual driver in non-small cell lung carcinoma – therapeutic dilemma. IJMIO 2021;7:16-19. [DOI: 10.25259/ijmio_22_2021] [Reference Citation Analysis]
8 He C, Wei C, Wen J, Chen S, Chen L, Wu Y, Shen Y, Bai H, Zhang Y, Chen X, Li X. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients. J Cancer Res Clin Oncol 2021. [PMID: 34693477 DOI: 10.1007/s00432-021-03818-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ma Y, Zhao J, Du Y, Wang R, Ji X, Wu J, Guo X, Liu Y, Zhang Y. Multigene Combined Detection by RT-qPCR Using Cytological Specimens. Acta Cytol 2021;65:393-402. [PMID: 34343999 DOI: 10.1159/000514821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Lu Z, Wang X, Luo Y, Wei J, Zeng Z, Xiong Q, Cai J, Liu A. EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report. Onco Targets Ther 2021;14:2823-8. [PMID: 33935502 DOI: 10.2147/OTT.S294635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zhao D, Fan J, Peng L, Huang B, Zhu Y, Shi H, Dai X, Nie X. Two different patterns of lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement. Tumori 2021;:3008916211005546. [PMID: 33818198 DOI: 10.1177/03008916211005546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Cortot A. Cas clinique n° 2 : Nouvelles technologies appliquées à l’oncologie thoracique. Revue des Maladies Respiratoires Actualités 2021;13:1S11-1S15. [DOI: 10.1016/s1877-1203(21)00004-5] [Reference Citation Analysis]
13 Cipriano É, Magalhães H, Tavares C, Pinto J, Cirnes L, Estevinho F. Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review. Porto Biomed J 2021;6:e124. [PMID: 33884320 DOI: 10.1097/j.pbj.0000000000000124] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Smolle E, Taucher V, Lindenmann J, Jost PJ, Pichler M. Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:699. [PMID: 33572278 DOI: 10.3390/cancers13040699] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
15 Kang M, Park C, Kim SH, Yoon SW, Suh KJ, Kim YJ, Ock CY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Transl Lung Cancer Res 2021;10:699-711. [PMID: 33718015 DOI: 10.21037/tlcr-20-893] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
16 Zhang Y, Wang H, Wang X, Li S, Fang H. Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report. Clin Lung Cancer 2021:S1525-7304(21)00011-5. [PMID: 33640300 DOI: 10.1016/j.cllc.2021.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Lee KC, Koh J, Chung DH, Jeon YK. A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma. J Pathol Transl Med 2021;55:139-44. [PMID: 33472332 DOI: 10.4132/jptm.2020.12.16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Zhang R, Dong L, Yu J. Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors. Front Oncol 2020;10:544579. [PMID: 33520689 DOI: 10.3389/fonc.2020.544579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Novaes LAC, Sussuchi da Silva L, De Marchi P, Cavagna RO, de Paula FE, Zanon MF, Evangelista AF, Albino da Silva EC, Duval da Silva V, Leal LF, Reis RM. Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients. Transl Lung Cancer Res 2021;10:292-303. [PMID: 33569313 DOI: 10.21037/tlcr-20-740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Recondo G, Friboulet L. Therapeutic strategies to overcome ALK resistance in lung cancer. Therapeutic Strategies to Overcome ALK Resistance in Cancer 2021. [DOI: 10.1016/b978-0-12-821774-0.00004-8] [Reference Citation Analysis]
21 Joung KI, Song JH, Suh K, Lee SM, Jun JH, Park T, Suh DC. Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients. BioDrugs 2021;35:61-73. [PMID: 33331991 DOI: 10.1007/s40259-020-00459-2] [Reference Citation Analysis]
22 Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, Zhang S, Jing W, Ma J, Han C. Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review. Front Oncol 2020;10:610923. [PMID: 33363040 DOI: 10.3389/fonc.2020.610923] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
23 Li M, Hou X, Zhou C, Feng W, Jiang G, Long H, Yang S, Chen J, Wang N, Wang K, Chen L. Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055). Front Oncol 2020;10:1216. [PMID: 32974126 DOI: 10.3389/fonc.2020.01216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
24 Tao J, Sun D, Hou H. Role of YES1 amplification in EGFR mutation-positive non-small cell lung cancer: Primary resistance to afatinib in a patient. Thorac Cancer 2020;11:2736-9. [PMID: 32744377 DOI: 10.1111/1759-7714.13583] [Reference Citation Analysis]
25 Ma Y, Du Y, Wang R, Ji X, Wu J, Liu Y, Guo X, Zhang Y. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens. Pathol Res Pract 2020;216:153036. [PMID: 32703499 DOI: 10.1016/j.prp.2020.153036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhang X, Jiang Y, Yu H, Xia H, Wang X. A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients. World J Surg Oncol 2020;18:172. [PMID: 32677962 DOI: 10.1186/s12957-020-01947-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Yan Y, Jiang G, Ma W, Li T, Wang L. Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC. Clin Lung Cancer 2020;21:562-7. [PMID: 32622727 DOI: 10.1016/j.cllc.2020.05.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Fan J, Wu J, Huang B, Zhu Y, Shi H, Dai X, Nie X. Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report. Diagn Pathol 2020;15:42. [PMID: 32375829 DOI: 10.1186/s13000-020-00969-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tsukumo Y, Naito M, Suzuki T. Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line. PLoS One 2020;15:e0229712. [PMID: 32130260 DOI: 10.1371/journal.pone.0229712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
30 Zhao Y, Wang S, Zhang B, Qiao R, Xu J, Zhang L, Zhang Y, Han B. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. Target Oncol 2019;14:169-78. [PMID: 30888598 DOI: 10.1007/s11523-019-00628-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
31 Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol 2019;42:337-44. [PMID: 30741758 DOI: 10.1097/COC.0000000000000508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
32 Chang WC, Kim HK, Shin BK. Clinicopathological features and diagnostic methods of ALK fusion‑positive non‑small cell lung cancer in Korea. Oncol Rep 2020;43:218-28. [PMID: 31746406 DOI: 10.3892/or.2019.7399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
33 Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Clin Lung Cancer 2020;21:e182-90. [PMID: 31839532 DOI: 10.1016/j.cllc.2019.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
34 Rossi G, Bargellini I, Bonifazi M, Camplese P, Candoli P, Ceron L, Gasparini S, Granone PL, Grossi F, Iezzi R, Marchetti A, Maur M, Poletti V, Posa A, Trisolini R, Veltri A, Zito-marino F. Optimised Tumour Sampling and Processing by a Multidisciplinary Approach for an Accurate Diagnosis in Non-Small Cell Lung Cancer. EMJ Oncol 2019. [DOI: 10.33590/emjoncol/10311320] [Reference Citation Analysis]
35 Zhou X, Shou J, Sheng J, Xu C, Ren S, Cai X, Chu Q, Wang W, Zhen Q, Zhou Y, Li W, Pan H, Li H, Sun T, Cheng H, Wang H, Lou F, Rao C, Cao S, Pan H, Fang Y. Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cancer Sci 2019;110:3382-90. [PMID: 31444835 DOI: 10.1111/cas.14177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
36 Heo JY, Park C, Keam B, Ock CY, Kim M, Kim TM, Kim DW, Kim SH, Kim YJ, Lee JS, Heo DS. The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer. Thorac Cancer 2019;10:2117-23. [PMID: 31509890 DOI: 10.1111/1759-7714.13195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
37 Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, Sørensen JB. Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers (Basel) 2019;11:E923. [PMID: 31266248 DOI: 10.3390/cancers11070923] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 16.3] [Reference Citation Analysis]
38 Dhieb D, Belguith I, Capelli L, Chiadini E, Canale M, Bravaccini S, Yangui I, Boudawara O, Jlidi R, Boudawara T, Calistri D, Keskes LA, Ulivi P. Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma. Cells 2019;8:E514. [PMID: 31141932 DOI: 10.3390/cells8060514] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
39 Liu J, Mu Z, Liu L, Li K, Jiang R, Chen P, Zhou Q, Jin M, Ma Y, Xie Y, Xiang J, Li B, Ma Y, Mao X, Zhang L, Zhang T, Wu D. Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients. Drug Des Devel Ther 2019;13:1809-17. [PMID: 31213769 DOI: 10.2147/DDDT.S196189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
40 Zhu WY, Fang KX, He JY, Cui R, Zhang YK, Le HB. A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm. Dis Markers 2019;2019:8435893. [PMID: 31191756 DOI: 10.1155/2019/8435893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Del Ben F, Bulfoni M, Turetta M, Brisotto G, Steffan A, Curcio F. Biopsia liquida: una review. Riv Ital Med Lab 2019;15. [DOI: 10.23736/s1825-859x.19.00004-5] [Reference Citation Analysis]
42 Fan J, Dai X, Wang Z, Huang B, Shi H, Luo D, Zhang J, Cai W, Nie X, Hirsch FR. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions. Clin Lung Cancer 2019;20:e517-30. [PMID: 31138506 DOI: 10.1016/j.cllc.2019.04.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
43 Zhuang X, Zhao C, Li J, Su C, Chen X, Ren S, Li X, Zhou C. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med 2019;8:2858-66. [PMID: 31016879 DOI: 10.1002/cam4.2183] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
44 Chen M, Xu Y, Zhao J, Zhong W, Zhang L, Bi Y, Wang M. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. EBioMedicine 2019;42:304-10. [PMID: 30878600 DOI: 10.1016/j.ebiom.2019.03.023] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
45 Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M, Corvaja C, Arpino G, Del Mastro L, De Placido S, De Laurentiis M, Cristofanilli M, Puglisi F. Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? Cancer Treat Rev. 2019;73:73-83. [PMID: 30682661 DOI: 10.1016/j.ctrv.2019.01.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 16.5] [Reference Citation Analysis]
46 Pal P, Cabanero M, Tsao M. Pulmonary Adenocarcinoma—Pathology and Molecular Testing. Pulmonary Adenocarcinoma: Approaches to Treatment 2019. [DOI: 10.1016/b978-0-323-55433-6.00002-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Purkayastha A, Kapoor A, Singh HP, Sarin A, Sengupta P, Singh S, Bisht N, Husain A. Concomitant expression of exon 19 mutation epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangement in metastatic adenocarcinoma lung responsive to crizotinib. Lung India 2018;35:527-9. [PMID: 30381567 DOI: 10.4103/lungindia.lungindia_30_18] [Reference Citation Analysis]
48 Wang X, Zhong D. [Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2018;21:686-91. [PMID: 30201068 DOI: 10.3779/j.issn.1009-3419.2018.09.07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
49 Zeng L, Li Y, Xiao L, Xiong Y, Liu L, Jiang W, Heng J, Qu J, Yang N, Zhang Y. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer. Onco Targets Ther 2018;11:6937-45. [PMID: 30410351 DOI: 10.2147/OTT.S176273] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
50 Rim K. Genetic Biomarkers and Their Applications to Prevent Occupational Diseases: A Literature Review. Toxicol Environ Health Sci 2018;10:147-156. [DOI: 10.1007/s13530-018-0358-0] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
51 Zhang K, Chen H, Wang Y, Yang L, Zhou C, Yin W, Wang G, Mao X, Xiang J, Li B, Zhang T, Fei S. Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients. Oncol Res 2019;27:575-82. [PMID: 30131091 DOI: 10.3727/096504018X15344979253618] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
52 Wei DM, Chen WJ, Meng RM, Zhao N, Zhang XY, Liao DY, Chen G. Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients. Respir Res 2018;19:150. [PMID: 30103737 DOI: 10.1186/s12931-018-0843-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
53 Cortinovis D, Canova S, Abbate MI, Colonese F, Cogliati V, Bidoli P. Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse. Future Oncol 2018;14:2303-17. [PMID: 30088419 DOI: 10.2217/fon-2018-0066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
54 Artaç M, Korkmaz L, Karaağaç M, Kaya B, Poyraz N, Özön H, Er Z, Tavlı L. A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib. Journal of Oncological Sciences 2018;4:111-3. [DOI: 10.1016/j.jons.2018.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. Korean J Intern Med 2019;34:1116-24. [PMID: 29950554 DOI: 10.3904/kjim.2018.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
56 Cabanero M, Tsao MS. Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer. Curr Oncol 2018;25:S38-44. [PMID: 29910646 DOI: 10.3747/co.25.3761] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
57 Kwon D, Koh J, Kim S, Go H, Min HS, Kim YA, Kim DK, Jeon YK, Chung DH. Overexpression of endoplasmic reticulum stress-related proteins, XBP1s and GRP78, predicts poor prognosis in pulmonary adenocarcinoma. Lung Cancer 2018;122:131-7. [PMID: 30032821 DOI: 10.1016/j.lungcan.2018.06.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
58 Berradi H, Kaanane H, El Kadmiri N, Nadifi S. Concomitance of EGFR mutations and ALK rearrangement in patients with Lung Cancer. Gene Reports 2018;11:196-204. [DOI: 10.1016/j.genrep.2018.03.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
59 Jakobsen JN, Santoni-Rugiu E, Grauslund M, Melchior L, Sørensen JB. Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment. Oncotarget 2018;9:26195-208. [PMID: 29899852 DOI: 10.18632/oncotarget.25490] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
60 Song JU, Lee J. Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis. Yonsei Med J 2018;59:211-8. [PMID: 29436188 DOI: 10.3349/ymj.2018.59.2.211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 Yokoyama A, Tamura A, Miyakawa K, Kusaka K, Shimada M, Hirose T, Matsui H, Kitani M, Hebisawa A, Ohta K. Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib. Intern Med 2018;57:2377-82. [PMID: 29526950 DOI: 10.2169/internalmedicine.0383-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
62 Hu W, Liu Y, Chen J. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer. Oncotarget 2017;8:25046-54. [PMID: 28212572 DOI: 10.18632/oncotarget.15337] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
63 Hu H, Qing Lin W, Zhu Q, Wen Yang X, Wang HD, Kuang YK. Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis. Oncotarget 2016;7:81090-8. [PMID: 27835601 DOI: 10.18632/oncotarget.13191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
64 Lou NN, Zhang XC, Chen HJ, Zhou Q, Yan LX, Xie Z, Su J, Chen ZH, Tu HY, Yan HH, Wang Z, Xu CR, Jiang BY, Wang BC, Bai XY, Zhong WZ, Wu YL, Yang JJ. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Oncotarget 2016;7:65185-95. [PMID: 27533086 DOI: 10.18632/oncotarget.11218] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
65 Wang LY, Cui JJ, Guo AX, Yin JY. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther 2018;11:529-38. [PMID: 29416353 DOI: 10.2147/OTT.S136579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
66 Ye M, Zhang X, Li N, Zhang Y, Jing P, Chang N, Wu J, Ren X, Zhang J. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget 2016;7:12289-304. [PMID: 26802023 DOI: 10.18632/oncotarget.6935] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
67 Tian H, Zhang X, Yang J, Guo W, Chen Z, Wang Z, Wu Y. Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. Lung Cancer 2017;114:90-5. [DOI: 10.1016/j.lungcan.2017.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
68 Sánchez NS, Mills GB, Mills Shaw KR. Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics 2017;18:1525-39. [PMID: 29061079 DOI: 10.2217/pgs-2017-0094] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
69 Tang Z, Zhang J, Lu X, Wang W, Chen H, Robinson MK, Cheng J, Tang G, Medeiros LJ. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. Mod Pathol 2018;31:307-12. [DOI: 10.1038/modpathol.2017.109] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
70 Ma W, Guo L, Shan L, Liu X, Lyu N, Ying J. Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis. Sci Rep 2017;7:10961. [PMID: 28887531 DOI: 10.1038/s41598-017-11453-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
71 Li Y, Su S, Cai G, Lin Q, Zhou Y, Ouyang J, Chen B, Ye J, Wu X, Chen C. Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature. Mol Clin Oncol 2017;7:173-82. [PMID: 28781781 DOI: 10.3892/mco.2017.1306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Tabchi S, Kourie HR, Klastersky J. Concurrent driver mutations/rearrangements in non-small-cell lung cancer. Curr Opin Oncol 2017;29:118-22. [PMID: 28027105 DOI: 10.1097/CCO.0000000000000353] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
73 Mao Y, Wu S. ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma. Onco Targets Ther 2017;10:3399-404. [PMID: 28744144 DOI: 10.2147/OTT.S133349] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
74 Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. Clin Lung Cancer 2018;19:35-41. [PMID: 28757336 DOI: 10.1016/j.cllc.2017.06.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
75 Kim CG, Shim HS, Hong MH, Cha YJ, Heo SJ, Park HS, Kim JH, Lee JG, Lee CY, Cho BC, Kim HR. Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. Oncotarget 2017;8:65111-22. [PMID: 29029416 DOI: 10.18632/oncotarget.17786] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
76 Caliez J, Monnet I, Pujals A, Rousseau-bussac G, Jabot L, Boudjemaa A, Leroy K, Chouaid C. Adénocarcinome bronchique avec mutation de l’ EGFR et réarrangement ALK concomitants. Revue des Maladies Respiratoires 2017;34:576-80. [DOI: 10.1016/j.rmr.2016.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
77 Martín Martorell P, Huerta M, Compañ Quilis A, Abellán R, Seda E, Blesa S, Chaves FJ, Dualde Beltrán D, Roselló Keränen S, Franco J, Insa A. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients. Clin Lung Cancer 2017;18:e395-402. [PMID: 28550959 DOI: 10.1016/j.cllc.2017.04.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
78 Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget 2017;8:59889-900. [PMID: 28938691 DOI: 10.18632/oncotarget.17431] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
79 Thumallapally N, Yu H, Farhan M, Ibrahim U, Odiami M. Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature. J Pharm Pract 2018;31:244-8. [PMID: 28438075 DOI: 10.1177/0897190017704751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
80 Kwon D, Koh J, Kim S, Go H, Kim YA, Keam B, Kim TM, Kim D, Jeon YK, Chung DH. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. Lung Cancer 2017;106:131-7. [DOI: 10.1016/j.lungcan.2017.02.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
81 Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M. Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Journal of Thoracic Oncology 2017;12:681-8. [DOI: 10.1016/j.jtho.2016.12.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 6.8] [Reference Citation Analysis]
82 Kim S, Koh J, Kwon D, Keam B, Go H, Kim YA, Jeon YK, Chung DH. Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. Eur J Cancer 2017;75:141-9. [PMID: 28222308 DOI: 10.1016/j.ejca.2017.01.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 11.0] [Reference Citation Analysis]
83 Gow CH, Chang HT, Lim CK, Liu CY, Chen JS, Shih JY. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas. Genes Chromosomes Cancer 2017;56:373-81. [PMID: 28063177 DOI: 10.1002/gcc.22442] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
84 Proto C, Russo GL, Corrao G, Ganzinelli M, Facchinetti F, Minari R, Tiseo M, Garassino MC. Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms. Tumori 2017;103:325-37. [DOI: 10.5301/tj.5000663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
85 Crizotinib. Reactions Weekly 2016;1631:58-58. [DOI: 10.1007/s40278-016-23836-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Chang YS, Choi CM, Lee JC. Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma. Tuberc Respir Dis (Seoul) 2016;79:248-56. [PMID: 27790276 DOI: 10.4046/trd.2016.79.4.248] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
87 Rocco G, Morabito A, Leone A, Muto P, Fiore F, Budillon A. Management of non-small cell lung cancer in the era of personalized medicine. The International Journal of Biochemistry & Cell Biology 2016;78:173-9. [DOI: 10.1016/j.biocel.2016.07.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
88 Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, Kühl H, Stuschke M, Schmid KW, Schuler M. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. J Thorac Oncol 2017;12:54-64. [PMID: 27575422 DOI: 10.1016/j.jtho.2016.08.137] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
89 Facchinetti F, Tiseo M, Di Maio M, Graziano P, Bria E, Rossi G, Novello S. Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Transl Lung Cancer Res 2016;5:301-21. [PMID: 27413712 DOI: 10.21037/tlcr.2016.06.10] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
90 Zhang YC, Zhou Q, Wu YL. Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. Expert Opin Pharmacother 2016;17:1693-701. [PMID: 27359268 DOI: 10.1080/14656566.2016.1208171] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
91 Chen YL, Lee CT, Lu CC, Yang SC, Chen WL, Lee YC, Yang CH, Peng SL, Su WC, Chow NH, Ho CL. Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis. PLoS One 2016;11:e0158125. [PMID: 27352172 DOI: 10.1371/journal.pone.0158125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
92 Giroux-Leprieur E, Fallet V, Cadranel J, Wislez M. Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. Lung Cancer (Auckl) 2016;7:83-90. [PMID: 28210164 DOI: 10.2147/LCTT.S99303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
93 Ma D, Hao X, Wang Y, Xing P, Li J. Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Thorac Cancer 2016;7:452-8. [PMID: 27385988 DOI: 10.1111/1759-7714.12353] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
94 Lee T, Lee B, Choi YL, Han J, Ahn MJ, Um SW. Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. J Pathol Transl Med 2016;50:197-203. [PMID: 27086595 DOI: 10.4132/jptm.2016.03.09] [Cited by in Crossref: 49] [Cited by in F6Publishing: 64] [Article Influence: 7.0] [Reference Citation Analysis]
95 Ju L, Han M, Zhao C, Li X. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient. Lung Cancer 2016;95:94-7. [PMID: 27040858 DOI: 10.1016/j.lungcan.2016.03.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
96 Galetta D, Catino A, Misino A. Concomitant EGFR mutations/ALK rearrangements: beyond a simple dual target. Transl Lung Cancer Res 2016;5:143-4. [PMID: 26958510 DOI: 10.3978/j.issn.2218-6751.2016.01.09] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
97 Kim EY, Cho EN, Park HS, Hong JY, Lim S, Youn JP, Hwang SY, Chang YS. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther 2016;17:237-45. [PMID: 26785607 DOI: 10.1080/15384047.2016.1139235] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 8.1] [Reference Citation Analysis]
98 Kim MA, Kang J, Kim I, Kim T, Kim SJ, Sung SW, Huo SM. Coexistence of an <i>EGFR</i> Mutation and an <i>ALK</i> Rearrangement in a Patient with Lung Adenocarcinoma: a Case Report. Korean J Med 2016;90:72-77. [DOI: 10.3904/kjm.2016.90.1.72] [Reference Citation Analysis]
99 Takenaka T, Yamazaki K, Miura N, Mori R, Matsumoto R, Momosaki S, Takeo S. Second Primary Lung Adenocarcinoma Harboring EML4-ALK After Surgically Resected EGFR Positive Lung Adenocarcinoma. Clin Lung Cancer 2016;17:e13-5. [PMID: 26704814 DOI: 10.1016/j.cllc.2015.11.005] [Reference Citation Analysis]
100 Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, Calistri D, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. Clin Lung Cancer 2016;17:384-90. [PMID: 26712101 DOI: 10.1016/j.cllc.2015.11.004] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
101 Giroux Leprieur E, Fallet V, Wislez M. [Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer]. Bull Cancer 2015;102:1053-7. [PMID: 26597476 DOI: 10.1016/j.bulcan.2015.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
102 Ragazzi M, Tamagnini I, Bisagni A, Cavazza A, Pagano M, Baldi L, Boni C, Cantile F, Barbieri F, Nicoli D, Sartori G, de Biase D, Gardini G, Rossi G. Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas. J Clin Pathol 2016;69:440-7. [DOI: 10.1136/jclinpath-2015-203348] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
103 Beau-faller M, Renaud S, Weingertner N, Lindner V, Emprou C, Le Van Quyen P, Legrain M, Voegeli A, Chenard M, Pencreach E, Gaub M, Schneider A, Guerin É. Carcinomes bronchiques non à petites cellules (CBNPC) métastatiques, mutés ou réarrangés : comment déterminer la cible ? Revue des Maladies Respiratoires Actualités 2015;7:476-496. [DOI: 10.1016/s1877-1203(16)30031-3] [Reference Citation Analysis]
104 Pfarr N, Stenzinger A, Penzel R, Warth A, Dienemann H, Schirmacher P, Weichert W, Endris V. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer. Genes Chromosomes Cancer 2016;55:30-44. [PMID: 26394895 DOI: 10.1002/gcc.22297] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
105 Lei YY, Yang JJ, Zhang XC, Zhong WZ, Zhou Q, Tu HY, Tian HX, Guo WB, Yang LL, Yan HH, Chen HJ, Xie Z, Su J, Han JF, Wu YL. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC. Clin Lung Cancer 2016;17:223-31. [PMID: 26454342 DOI: 10.1016/j.cllc.2015.09.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
106 Sahnane N, Frattini M, Bernasconi B, Zappa F, Schiavone G, Wannesson L, Antonelli P, Balzarini P, Sessa F, Mazzucchelli L, Tibiletti MG, Martin V. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. Clin Lung Cancer 2016;17:56-61. [PMID: 26381283 DOI: 10.1016/j.cllc.2015.08.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
107 Rossi G, Baldi L, Barbieri F, Bertolini F, Tiseo M. Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer. Annals of Oncology 2015;26:1035-6. [DOI: 10.1093/annonc/mdv067] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
108 Passaro A, Barberis M, Catania C, Pessina S, de Marinis F. Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the making. Ann Oncol 2015;26:1270-1. [PMID: 25791634 DOI: 10.1093/annonc/mdv150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Zimmermann W. Unerwartet häufig duale Mutationen. Info Onkol 2015;18:28-28. [DOI: 10.1007/s15004-015-0774-0] [Reference Citation Analysis]
110 Zimmermann W. Lungenkrebs: Unerwartet oft duale Mutationen. Im Focus Onkologie 2015;18:28-28. [DOI: 10.1007/s15015-015-1565-z] [Reference Citation Analysis]